Kidney Cancer News and Updates That Patients May Have Missed in 2020

January 5, 2021
CURE staff

A roundup of some kidney cancer news and updates that occurred in 2020 that patients may have missed.

There were several updates in the field of kidney cancer in 2020. Here, CURE® looks back at some of the news and updates in the field that patients may have missed.

  • At five years of follow-up, treatment with Opdivo (nivolumab) demonstrated superior overall survival and objective response rates, compared with Afinitor (everolimus), in patients with previously treated advanced or metastatic renal cell carcinoma (RCC), according to results from the phase 3 Checkmate-025 study. READ MORE.
  • Patients with advanced, previously untreated RCC may soon have a new option in the novel combination of Opdivo (nivolumab) and Cabometyx (cabozantinib), according to phase 3 results of the CheckMate-9ER trial. READ MORE.
  • Birth weight, height and childhood body mass index (BMI) are associated with adult RCC, meaning they could be valuable predictors for a person’s risk of disease, according to new findings published in the European Journal of Epidemiology. READ MORE.
  • Data presented at the 2020 ASCO Virtual Scientific Program demonstrated that treatment with savolitinib showed encouraging efficacy and an improved safety data over standard-of-care Sutent (sunitinib) in patients with MET-driven papillary RCC. READ MORE.
  • Treatment with Cabometyx (cabozantinib) in combination with Tecentriq (atezolizumab) demonstrated promising clinical activity in patients with advanced clear cell RCC, according to data presented at the 2020 ESMO Virtual Congress. READ MORE.
  • Data from a phase 2 study presented during the 2020 ASCO Virtual Scientific Program demonstrated that Avastin (bevacizumab) in combination with Tarceva (erlotinib) was well tolerated and produced encouraging clinical outcomes in patients with advanced hereditary leiomyomatosis and RCC or sporadic papillary RCC. READ MORE.
  • Fotivda (tivozanib) significantly improved survival, compared with Nexavar (sorafenib), in patients with highly relapsed or refractory metastatic RCC, according to results from the phase 3 TIVO-3 trial presented at the 2020 ASCO Virtual Scientific Program. READ MORE.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.